DelistedThis company is no longer listed on the London Stock Exchange.
Synairgen plc
Financial Health
Going concern
No material uncertainty
Audit opinion
Unqualified
Post year-end
3 adverse
Principal risks
2
Recent RNS announcements
No recent announcements
Annual Reports
27 Aug 2026
Annual Report and Accounts (to 2025-12-31)
7 Jul 2024
Annual Report and Accounts (to 2023-12-31)
6 Jul 2023
Annual Report and Accounts (to 2022-12-31)
Directors (9)
Paul KopejtkaNon Executive Chairman
–
DM
Dr Mark Parry-BillingsExecutive Chairman
2 yrs 1 mos
ZP
Zane PadmanCEO
–
JT
Joseph Tregonning ColliverChief Executive Officer
3 yrs
MM
Martin MurphyNon-Executive Director
–
Company details
Synairgen is a company that specializes in respiratory drug research, development, and marketing. Their primary objective is to create and distribute SNG001, an inhaled interferon beta treatment for COVID-19 that directly targets the lungs as an antiviral solution.
Synairgen is a company that specializes in respiratory drug research, development, and marketing. Their primary objective is to create and distribute SNG001, an inhaled interferon beta treatment for COVID-19 that directly targets the lungs as an antiviral solution.